Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity
Poojitha Sitaram, Bradley Uyemura, Subramaniam Malarkannan, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 23, pp. 5821-5821
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Diana Gumber, Leo D. Wang
EBioMedicine (2022) Vol. 77, pp. 103941-103941
Open Access | Times Cited: 229
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 178
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Rangarirai Makuku, Neda Khalili, Sepideh Razi, et al.
Journal of Immunology Research (2021) Vol. 2021, pp. 1-15
Open Access | Times Cited: 104
Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways
Jiaxin Liu, Yicheng Cheng, Ming Zheng, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 57
Engineered Treg cells: The heir to the throne of immunotherapy
Adriana Stucchi, Federica Maspes, Ely Montee-Rodrigues, et al.
Journal of Autoimmunity (2023) Vol. 144, pp. 102986-102986
Closed Access | Times Cited: 22
The role of LncRNAs in tumor immunotherapy
Xuan Pan, Chenchen Li, Jifeng Feng
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 22
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
Hui Chen, Xiangna Guan, Chi He, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 4, pp. 237-250
Closed Access | Times Cited: 8
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
Vladimir Laletin, P Bernard, Cathy Costa Da Silva, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 5, pp. e005845-e005845
Open Access | Times Cited: 14
Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy
Jelter Van Hoeck, Kevin Braeckmans, Stefaan C. De Smedt, et al.
Biomaterials (2022) Vol. 286, pp. 121510-121510
Closed Access | Times Cited: 21
Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
Lisa Schlicher, Luke G. Green, Andrea Romagnani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells
Hao‐Qi Wang, Fei Li, Yuanyuan Feng, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113971-113971
Closed Access
Germline mutation in Cbl proto-oncogene B is associated with inherited thrombocytopenia and predisposes megakaryocytes to ferroptosis
Xiang Xiao, Rongli Xie, Yang Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 5, pp. 167765-167765
Closed Access
A distinct priming phase regulates CD8 T cell immunity by orchestrating paracrine IL-2 signals
Katarzyna Jobin, Deeksha Seetharama, Lennart Rüttger, et al.
Science (2025) Vol. 388, Iss. 6743
Closed Access
CAR-T Cell Therapy
Aamir Ahmad
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4303-4303
Open Access | Times Cited: 29
Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation
M. Ahn, Eun Hye Kim, Yunha Choi, et al.
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0305261-e0305261
Open Access | Times Cited: 3
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
Liselotte Tas, Inge Jedema, John B.A.G. Haanen
Current Opinion in Oncology (2023)
Open Access | Times Cited: 9
Identification of Immuno-Inflammation-Related Biomarkers for Acute Myocardial Infarction Based on Bioinformatics
Hongjun You, Mengya Dong
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 3283-3302
Open Access | Times Cited: 8
Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
Bahman Abedi Kiasari, Arash Abbasi, Nadia Ghasemi Darestani, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109365-109365
Closed Access | Times Cited: 13
Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization
Louis S. Chupak, Michael Wichroski, Xiaofan Zheng, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 7, pp. 929-935
Closed Access | Times Cited: 7
DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing
В. М. Лалетин, P Bernard, Camille Montersino, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event
Juan Bautista De Sanctis, Jenny Garmendia, Hana Duchová, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2630-2630
Open Access | Times Cited: 2
Beyond Lipid Signaling: Pleiotropic Effects of Diacylglycerol Kinases in Cellular Signaling
Jae Ang Sim, Jaehong Kim, Dongki Yang
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6861-6861
Open Access | Times Cited: 17
Identification of Phomoxanthone A and B as Protein Tyrosine Phosphatase Inhibitors
Runlei Yang, Qian Dong, Huibin Xu, et al.
ACS Omega (2020) Vol. 5, Iss. 40, pp. 25927-25935
Open Access | Times Cited: 13
Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
Xiuzhen Zhang, Tong Meng, Shuaishuai Cui, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 12
Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer
Imtiaz Mahmood Tahir, Abdur Rauf, Huma Mehboob, et al.
Human Antibodies (2022) Vol. 30, Iss. 3, pp. 131-150
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top